Restart Life Sciences Corp. (NMLSF)
Restart Life Sciences Corp. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.07, up 38.47% on the session, giving a market capitalisation of $2.5M. On trailing twelve-month figures it carries a trailing P/E of -1.87, a net margin of -667.3%. Its beta of -0.80 implies it has historically moved less than the broad market.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Restart Life Sciences Corp. is most often compared with the following Healthcare names: